BRISTOL MYERS SQUIBB CO Treasury Stock 2007-2026 | BMY
Beta
What is treasury stock?
Treasury stock represents shares that were previously issued and later repurchased by the company, reducing total stockholders' equity.
What is BRISTOL MYERS SQUIBB CO's current treasury stock?
BRISTOL MYERS SQUIBB CO (BMY) annual treasury stock for 2025 was $43.58B, a 0.17% decline from 2024. BRISTOL MYERS SQUIBB CO treasury stock for the quarter ending March 31, 2026 was $43.52B.
What was BRISTOL MYERS SQUIBB CO's treasury stock in 2024?
BRISTOL MYERS SQUIBB CO annual treasury stock for 2024 was $43.66B, a 0.25% decline from 2023.
What was BRISTOL MYERS SQUIBB CO's treasury stock in 2023?
BRISTOL MYERS SQUIBB CO annual treasury stock for 2023 was $43.77B, a 13.33% increase from 2022.
What is BRISTOL MYERS SQUIBB CO's 5-year treasury stock CAGR?
BRISTOL MYERS SQUIBB CO treasury stock grew at a compound annual growth rate (CAGR) of 10.68% from FY2020 to FY2025, going from $26.24B to $43.58B over 5 years.
Treasury Stock History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Stable
CAGR+10.7%
FY2020
$26.24B
→
FY2025
$43.58B
07080910111213141516171819202122232425
5 years selected
Treasury Stock History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $43.58B | -0.2% | 10-K |
| FY2024 | $43.66B | -0.3% | 10-K |
| FY2023 | $43.77B | +13.3% | 10-K |
| FY2022 | $38.62B | +23.5% | 10-K |
| FY2021 | $31.26B | +19.1% | 10-K |
| FY2020 | $26.24B | +3.5% | 10-K |
| FY2019 | $25.36B | +29.5% | 10-K |
| FY2018 | $19.57B | +1.7% | 10-K |
| FY2017 | $19.25B | +14.7% | 10-K |
| FY2016 | $16.78B | +1.3% | 10-K |
| FY2015 | $16.56B | -2.5% | 10-K |
| FY2014 | $16.99B | -4.5% | 10-K |
| FY2013 | $17.80B | -5.4% | 10-K |
| FY2012 | $18.82B | +8.2% | 10-K |
| FY2011 | $17.40B | -0.3% | 10-K |
| FY2010 | $17.45B | +0.5% | 10-K |
| FY2009 | $17.36B | +64.3% | 10-K |
| FY2008 | $10.57B | -0.2% | 10-K |
| FY2007 | $10.58B | - | 10-K |
Company: BRISTOL MYERS SQUIBB COTicker: BMYSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →